Abstract
Risk for Alzheimer's disease escalates dramatically with increasing age in the later decades of life. It is widely recognized that a preclinical condition in which memory loss is greater than would be expected for a person's age, referred to as amnestic mild cognitive impairment, may offer the best opportunity for intervention to treat symptoms and modify disease progression. Here we discuss a basis for age-related memory impairment, first discovered in animal models and recently isolated in the medial temporal lobe system of man, that offers a novel entry point for restoring memory function with the possible benefit in slowing progression to Alzheimer's disease.
MeSH terms
-
Aged
-
Aging / physiology
-
Aging / psychology
-
Alzheimer Disease / drug therapy
-
Alzheimer Disease / physiopathology*
-
Alzheimer Disease / prevention & control
-
Animals
-
Cognition Disorders / drug therapy
-
Cognition Disorders / physiopathology*
-
Cognition Disorders / prevention & control
-
Disease Models, Animal
-
Drug Design
-
Hippocampus / drug effects
-
Hippocampus / pathology
-
Hippocampus / physiopathology*
-
Humans
-
Memory / physiology
-
Memory Disorders / drug therapy
-
Memory Disorders / physiopathology*
-
Memory Disorders / prevention & control
-
Neural Pathways / drug effects
-
Neural Pathways / pathology
-
Neural Pathways / physiopathology
-
Nootropic Agents / pharmacology
-
Nootropic Agents / therapeutic use